Sequential Intravesical Chemoimmunotherapy with Mitomycin C and Bacillus Calmette-Guerin and with Bacillus Calmette-Guerin Alone in Patients with Carcinoma in Situ of the Urinary Bladder: Results of an EORTC Genito-Urinary Group Randomized Phase 2 Trial (30993)

Oosterlinck W., Kirkali Z., Sylvester R., da Silva F. C., Busch C., Algaba F., ...More

EUROPEAN UROLOGY, vol.59, no.3, pp.438-446, 2011 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 59 Issue: 3
  • Publication Date: 2011
  • Doi Number: 10.1016/j.eururo.2010.11.038
  • Journal Name: EUROPEAN UROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.438-446
  • Keywords: Bacillus Calmette-Guerin, Carcinoma in situ, Intravesical therapy, Mitomycin C, Non-muscle-invasive bladder cancer, Randomized clinical trial, Urinary bladder, EUROPEAN ORGANIZATION, UROTHELIAL CARCINOMA, CLINICAL-TRIALS, EAU GUIDELINES, III TRIAL, CANCER, BCG, INSTILLATION, COMBINATION, EPIRUBICIN
  • Dokuz Eylül University Affiliated: Yes


Background: Bacillus Calmette-Guerin (BCG) is the intravesical treatment of choice for carcinoma in situ (CIS).